In addition to these studies, there is an additional body of literature supporting GIPR agonism and not antagonism as a therapeutic strategy for T2D [23, 53, 54], and clinical testing is ongoing for a dual GIPR/GLP-1R agonist peptide [55, 56]. The gene discussed is GIPR; the disease is type 2 diabetes mellitus.